PeptideWiki

Retatrutide side effects: what the phase 2 and phase 3 TRIUMPH trials reported

Published by the PeptideWiki editorial team.

Retatrutide

Retatrutide side effects in trials were mostly GI, plus dysesthesia in up to 20.9% and a phase 2 heart rate rise. Highest-dose discontinuation was 7.7-18.2% vs 4.0-4.9% on placebo.

Retatrutide side effects in clinical trials have been mostly gastrointestinal, with nausea, diarrhea, constipation and vomiting leading the lists. Two other signals stand out: a skin-sensation effect called dysesthesia, and a heart rate rise first seen in phase 2. Discontinuation for adverse events ranged from 7.7% to 18.2% in the highest-dose arms of phase 3 trials, against 4.0% to 4.9% on placebo.

Retatrutide is an investigational once-weekly agonist at three receptors: GIP, GLP-1 and glucagon. It is not approved anywhere. Lilly says it plans to file with the FDA in the first quarter of 2027. All human safety data so far come from company-run trials. Phase 3 figures below are from topline releases and conference abstracts, not yet from full peer-reviewed papers.

Where the retatrutide side effects data come from

Four phase 3 TRIUMPH trials have reported topline results, plus one published phase 2 trial.

  • Phase 2 (NEJM, 2023): 338 adults with obesity, 48 weeks, several dose arms and placebo.
  • TRIUMPH-4 (December 2025): 445 adults with obesity or overweight and knee osteoarthritis, 68 weeks.
  • TRIUMPH-1 (May 2026): 2,339 adults with obesity or overweight and at least one weight-related condition, without diabetes, 80 weeks.
  • TRIUMPH-2 (July 2026): 1,152 adults with type 2 diabetes and obesity or overweight, 80 weeks.
  • TRIUMPH-3 (July 2026): 1,949 adults with BMI of 35 or more and established cardiovascular disease, 80 weeks.

The populations differ, so cross-trial comparisons need care. TRIUMPH-4 enrolled a heavier group, with 84% at BMI 35 or above. TRIUMPH-3 enrolled people with existing heart disease.

Gastrointestinal events across the TRIUMPH trials

GI effects were the most common adverse events in every trial. Rates rose with dose and were well above placebo. The table shows the highest-dose arm in each phase 3 trial.

TrialNausea (highest dose vs placebo)DysesthesiaStopped for adverse events
TRIUMPH-142.4% vs 14.8%12.5% vs 0.9%11.3% vs 4.9%
TRIUMPH-228.0% vs 8.0%7.3% vs 0.7%7.7% vs 4.9%
TRIUMPH-322.4% vs 5.8%6.4% vs 1.3%13.5% vs 4.8%
TRIUMPH-443.2% vs 10.7%20.9% vs 0.7%18.2% vs 4.0%

In TRIUMPH-1, vomiting reached 25.3% at the highest dose versus 4.8% on placebo. Diarrhea was 32.0% versus 13.5%, and constipation 26.1% versus 10.9%. Decreased appetite was listed in TRIUMPH-2, -3 and -4, reaching 12% to 19% in the higher-dose arms.

The phase 2 paper reported GI events as dose-related and mostly mild to moderate. Most occurred during dose escalation. A lower starting dose partly reduced them. Lilly describes the phase 3 event types as generally consistent with other incretin-based therapies, a class that includes semaglutide and tirzepatide.

Dysesthesia: the less familiar signal

Dysesthesia refers to abnormal or unpleasant skin sensations. In the phase 2 obesity trial it was reported in about 7% of retatrutide participants versus 1% on placebo, according to a Pharmacy Times summary of the data.

Phase 3 rates were higher in some trials. TRIUMPH-4 had the largest figure: 20.9% at the highest dose. TRIUMPH-1 reported 12.3% and 12.5% in its two upper arms. Rates were lower in the diabetes and cardiovascular trials, at 7.3% or less.

Lilly describes these events as generally mild to moderate. It says most resolved during treatment and rarely led to stopping. No mechanism has been confirmed in the sources reviewed. Full papers should show timing, duration and any link to the rate of weight loss.

Heart rate and cardiovascular data

The phase 2 NEJM trial found heart rate rose in a dose-dependent way. The increase peaked at 24 weeks and then declined. A cardiologist quoted by TCTMD at the time said it remained to be determined whether the finding becomes clinically important.

None of the phase 3 topline releases reported heart rate figures. They also did not report serious adverse event rates or deaths. Those details are expected in full publications.

TRIUMPH-3 included an exploratory look at major cardiovascular events. It was not powered for efficacy claims. For the five-part composite (MACE-5), the hazard ratio was 0.82 (95% CI 0.55 to 1.22). For the three-part composite (MACE-3), it was 1.12 (95% CI 0.64 to 1.96). Event counts were low and both intervals cross 1, so neither result shows a clear effect in either direction.

Discontinuation and what remains unknown

Stopping for adverse events generally rose with dose, but not always cleanly. In TRIUMPH-2, the middle-dose arm had a higher rate (11.6%) than the highest-dose arm (7.7%). In phase 2, rates ranged from 6% to 16% across retatrutide arms versus 0% on placebo.

TRIUMPH-4 had the highest rate, at 18.2%. Lilly said these discontinuations were highly correlated with baseline BMI. Some were for "perceived excessive weight loss." Among participants with BMI 35 or above, the highest-dose rate was 12.1%.

Urinary tract infections were slightly more common on retatrutide in TRIUMPH-1 and TRIUMPH-3. In TRIUMPH-2 the placebo rate (6.6%) sat between the retatrutide arms. TRIUMPH-3 showed hyperglycemia far more often on placebo (13.4%) than on retatrutide (3.1% to 3.9%), consistent with the drug's glucose-lowering effect.

Key gaps remain. Phase 3 heart rate data, serious adverse events, gallbladder and pancreatic events, and longer-term safety did not appear in the releases reviewed here. The trials ran 68 to 104 weeks. For context on how retatrutide compares with approved incretins, see semaglutide vs tirzepatide vs retatrutide and the retatrutide compound page. Related compounds are grouped under metabolic peptides, and approval status is tracked on the regulatory page.

Sources

  1. Eli Lilly: Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (May 21, 2026)
  2. Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (July 23, 2026)
  3. Eli Lilly: TRIUMPH-4 topline results for retatrutide in obesity and knee osteoarthritis (December 11, 2025)
  4. New England Journal of Medicine: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (June 2023)
  5. TCTMD: Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide (June 28, 2023)
  6. HCPLive: TRIUMPH-1: Retatrutide substantially lowers weight, BMI in patients with obesity or overweight (June 6, 2026)
  7. Pharmacy Times: What pharmacists need to know about retatrutide's TRIUMPH-1 phase 3 results (June 3, 2026)

Educational content only, not medical advice. Compounds discussed as research materials are for laboratory research use only and are not for human or veterinary use.

More from the blog